On May 15, 2015, the United States Food and Drug Administration (FDA) issued a warning that SGLT2 inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin) and Jardiance (empagliflozin) may cause ketoacidosis leading to prolonged hospitalization and possibly death. Ketoacidosis is a serious metabolic state where ketones accumulate in the blood in such high concentrations that the pH […]